Beyond Glucocorticoids for IgG4-Related Disease

This editorial evaluates emerging treatments for IgG4 related disease, a fibroinflammatory condition affecting multiple organs. While glucocorticoids remain the first line therapy, relapses are common, prompting exploration of alternative treatments. The MITIGATE trial demonstrated the efficacy of inebilizumab (an anti CD19 monoclonal antibody) in reducing disease flares compared to placebo (10.3% vs. 59.7% at 52 weeks) when combined with a glucocorticoid taper. However, long-term safety and comparative efficacy against other B cell targeting therapies like rituximab remain uncertain. The article underscores the need for further research on remission-maintenance strategies and potential applications of novel immunotherapies.

This editorial evaluates emerging treatments for IgG4 related disease, a fibroinflammatory condition affecting multiple organs. While glucocorticoids remain the first line therapy, relapses are common, prompting exploration of alternative treatments. The MITIGATE trial demonstrated the efficacy of inebilizumab (an anti CD19 monoclonal antibody) in reducing disease flares compared to placebo (10.3% vs. 59.7% at 52 weeks) when combined with a glucocorticoid taper. However, long-term safety and comparative efficacy against other B cell targeting therapies like rituximab remain uncertain. The article underscores the need for further research on remission-maintenance strategies and potential applications of novel immunotherapies.